Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Chief Medical Officer | October 13, 2020 | October 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Minerva Neurosciences, Inc.
Report date October 13, 2020 · Filed October 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2030-10-12 | Direct | 85,000 |
Reported balance
After 2020-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-13 · Grant · Acquired 85,000 · Balance 85,000 F1: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2020 Filed Oct 14, 2020 17:20 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-20-054804 · doc4.xml · derivative · entry 1 Davidson Michael · CIK 0001691467 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-10-12 F1 · derivative.exercise_date: One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022. Read SEC document |
| June 19, 2020 Filed Aug 17, 2020 16:27 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 137,784 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001209191-20-046948 · doc4.xml · derivative · entry 1 Davidson Michael · CIK 0001691467 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,784 Underlying: Common Stock · 137,784 shares Expires 2029-12-31 F1 · derivative.exercise_date: This option was granted by Issuer's Board of Directors on December 31, 2019 contingent upon stockholder approval of an amendment and restatement of Issuer's equity incentive plan to increase the number of shares available for issuance under such plan, which was received on June 19, 2020. This option vests 25% on December 31, 2020 and then in quarterly installments over 3 years thereafter. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:47 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 37,216 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001209191-20-001103 · doc4.xml · derivative · entry 1 Davidson Michael · CIK 0001691467 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,216 Underlying: Common Stock · 37,216 shares Expires 2029-12-30 F1 · derivative.exercise_date: This option vests 25% on December 31, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:40 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001209191-18-062459 · doc4.xml · derivative · entry 1 Davidson Michael · CIK 0001691467 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: This option vests 25% on December 11, 2019 and then in quarterly installments over 3 years thereafter. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:40 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001209191-17-065958 · doc4.xml · derivative · entry 1 Davidson Michael · CIK 0001691467 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: This option vests as to 25% of the shares on December 13, 2018 and then in quarterly installments over 3 years thereafter. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:39 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001209191-17-002130 · doc4.xml · derivative · entry 1 Davidson Michael · CIK 0001691467 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable as to 25% on January 3, 2018; the balance of the shares underlying the option shall vest and become exercisable in 12 successive equal quarterly installments, in each case so long as the Reporting Person provides continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.